These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28570008)

  • 1. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
    Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
    Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
    Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
    Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma.
    Miller K; Price JH; Dobbs SP; McClelland RH; Kennedy K; McCluggage WG
    J Clin Pathol; 2008 May; 61(5):652-7. PubMed ID: 18006668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
    Köbel M; Turbin D; Kalloger SE; Gao D; Huntsman DG; Gilks CB
    Int J Gynecol Pathol; 2011 Jul; 30(4):366-71. PubMed ID: 21623201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
    Ruba S; Doherty D; Stewart CJR
    Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
    Kwon HJ; Song SY; Kim HS
    Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
    Casey L; Singh N
    Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
    Bansal A; Srinivasan R; Rohilla M; Sundaram A; Rai B; Rajwanshi A; Suri V; Saha SC; Gupta N; Gupta P; Dey P
    Am J Clin Pathol; 2020 Jun; 154(1):103-114. PubMed ID: 32271370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.